Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.gastro.2024.04.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug repurposing in MASLD and MASH-cirrhosis: Targets and treatment approaches based on pathways analysis.
Prog Mol Biol Transl Sci
June 2024
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina; Clinical and Molecular Hepatology, Centro de Investigación Traslacional en Salud, Universidad Maimónides, Buenos Aires, Argentina; Facultad de Ciencias de la Salud, Universidad Maimónides, Buenos Aire
Designing and predicting novel drug targets to accelerate drug discovery for treating metabolic dysfunction-associated steatohepatitis (MASH)-cirrhosis is a challenging task. The presence of superimposed (nested) and co-occurring clinical and histological phenotypes, namely MASH and cirrhosis, may partly explain this. Thus, in this scenario, each sub-phenotype has its own set of pathophysiological mechanisms, triggers, and processes.
View Article and Find Full Text PDFCo-occurring MASLD and Diabetes Is Associated With Increased Incidence of Cardiovascular Events and Mortality.
Gastroenterology
September 2024
Yale University School of Medicine, New Haven, Connecticut.
A Machine Learning-Based Method for Detecting Liver Fibrosis.
Diagnostics (Basel)
September 2023
Medical Analysis Expert Group, Institute of Technology, Universidad de Castilla-La Mancha, 16071 Cuenca, Spain.
Cholecystectomy and Metabolic-associated steatotic liver disease (MASLD) are prevalent conditions in gastroenterology, frequently co-occurring in clinical practice. Cholecystectomy has been shown to have metabolic consequences, sharing similar pathological mechanisms with MASLD. A database of MASLD patients who underwent cholecystectomy was analysed.
View Article and Find Full Text PDF